📣 VC round data is live. Check it out!

DocMorris Valuation Multiples

Discover DocMorris' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Temple & Webster, Nice One, ASOS, JZJ Chain Drugstore and more.

DocMorris Overview

About DocMorris

DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.


Founded

1993

HQ

Switzerland

Employees

1.5K

Financials (LTM)

Revenue: $1B
EBITDA: ($48M)

EV

$549M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DocMorris Financials

DocMorris reported last 12-month revenue of $1B and negative EBITDA of ($48M).

In the same LTM period, DocMorris generated $331M in gross profit, ($48M) in EBITDA losses, and had net loss of ($141M).

Revenue (LTM)


DocMorris P&L

In the most recent fiscal year, DocMorris reported revenue of $1B and EBITDA of ($48M).

DocMorris is unprofitable as of last fiscal year, with gross margin of 21%, EBITDA margin of (4%), and net margin of (10%).

See analyst estimates for DocMorris
LTMLast FY202320242025202620272028
Revenue$1B$1B$1B$1B$1B
Gross Profit$331M$277M$260M$277M$314M
Gross Margin23%21%21%21%22%
EBITDA($48M)($48M)($72M)($48M)($63M)
EBITDA Margin(3%)(4%)(6%)(4%)(4%)
EBIT Margin(7%)(10%)(9%)(10%)(9%)
Net Profit($141M)($124M)$105M($124M)($170M)
Net Margin(10%)(10%)8%(10%)(12%)
Net Debt-$244M---

Financial data powered by Morningstar, Inc.

DocMorris Stock Performance

DocMorris has current market cap of $446M, and enterprise value of $549M.

Market Cap Evolution


DocMorris' stock price is $9.17.

DocMorris share price increased by 1.8% in the last 30 days, and by 12.9% in the last year.

DocMorris has an EPS (earnings per share) of $-2.56.

See more trading valuation data for DocMorris
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$549M$446M1.8%1.8%49.0%12.9%$-2.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DocMorris Valuation Multiples

DocMorris trades at 0.4x EV/Revenue multiple, and (11.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for DocMorris

EV / Revenue (LTM)


DocMorris Financial Valuation Multiples

As of June 2, 2026, DocMorris has market cap of $446M and EV of $549M.

DocMorris has a P/E ratio of (3.2x).

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.4x0.4x0.4x0.4x
EV/EBITDA(11.5x)(11.4x)(7.6x)(11.4x)(8.7x)
EV/EBIT(5.2x)(4.1x)(5.2x)(4.1x)(4.5x)
EV/Gross Profit1.7x2.0x2.1x2.0x1.7x
P/E(3.2x)(3.6x)4.2x(3.6x)(2.6x)
EV/FCF(4.5x)(7.8x)(3.7x)(7.8x)(3.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DocMorris Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DocMorris Margins & Growth Rates

DocMorris grew revenue by 9% and EBITDA by 31% in the last fiscal year.

In the most recent fiscal year, DocMorris reported gross margin of 21%, EBITDA margin of (4%), and net margin of (10%).

See estimated margins and future growth rates for DocMorris

DocMorris Margins

Last FY202420252026202720282029
Gross Margin21%21%22%23%
EBITDA Margin(4%)(4%)(4%)(2%)
EBIT Margin(10%)(10%)(9%)(5%)
Net Margin(10%)(10%)(12%)(7%)
FCF Margin(5%)(5%)(11%)(5%)

DocMorris Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%5%9%9%
Gross Profit Growth13%6%13%13%
EBITDA Growth31%(33%)31%(59%)
EBIT Growth(8%)26%(8%)(31%)
Net Profit Growth36%(218%)36%(40%)
FCF Growth114%(52%)114%(45%)

Data powered by FactSet, Inc. and Morningstar, Inc.

DocMorris Operational KPIs

DocMorris' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.3M for the same period.

DocMorris' Rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DocMorris' Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for DocMorris
LTMLast FY202320242025202620272028
Rule of 406%7%---
Bessemer Rule of X20%21%---
Revenue per Employee-$0.9M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue7%13%10%13%8%
G&A Expenses to Revenue-2%3%2%-
Opex to Revenue-32%29%32%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

DocMorris Competitors

DocMorris competitors include Temple & Webster, Nice One, ASOS, JZJ Chain Drugstore, Cawachi, Bed Bath & Beyond, BHG Group, Newegg, Wish and Fanli Digital Technology.

Most DocMorris public comparables operate across Consumer E-commerce, Pharmacies, Vertical E-commerce and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Temple & Webster0.8x0.8x26.6x22.9x
Nice One1.5x-47.3x-
ASOS0.3x0.4x6.7x5.7x
JZJ Chain Drugstore0.7x-5.6x-
Cawachi0.2x0.2x4.6x-
Bed Bath & Beyond0.3x0.3x(11.5x)(10.4x)
BHG Group0.6x0.6x7.7x7.8x
Newegg0.3x-69.0x-

This data is available for Pro users. Sign up to see all DocMorris competitors and their valuation data.

Start Free Trial

Acquisitions by DocMorris

DocMorris has acquired 3 companies to date.

Last acquisition by DocMorris was on July 16th 2020. DocMorris acquired TeleClinic for $50M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by DocMorris

TeleClinic
Apotal
PromoFarma.com
Description
TeleClinic is a Berlin-based digital healthcare platform connecting patients to licensed doctors via video consultations and app-based services across Germany. It offers primary care, prescriptions, sick notes, and specialist referrals through its telemedicine app available 24/7. Partnered with over 5,000 physicians, TeleClinic serves more than one million users with integrated pharmacy delivery and health record management. Launched in 2017, the company expanded to include mental health support and chronic condition management amid Germany's growing telehealth adoption.
Apotal is a German e-commerce platform specializing in over-the-counter medications, beauty products, and health supplies. The company operates shop.apotal.de as a marketplace for self-medication items and maintains a franchise network dedicated to diabetes management. Offerings include glucose monitors, insulin accessories, nutritional supplements, and patient education services tailored for chronic condition support across Europe.
PromoFarma.com is a Barcelona-based online marketplace specializing in consumer health, beauty, and baby products sourced directly from partner pharmacies across Spain. Shoppers access items from renowned brands like those in skincare and pharmaceuticals, with local pharmacies ensuring swift home delivery. The platform maintains a vast catalog alongside competitive pricing and reliable service standards. Recognized by Actualidad Económica as one of Spain's top startups, it earned awards for Best Beauty and Personal Care Webshop in 2014 and 2015. Operations center in Spain, with the model designed for expansion into other European markets through pharmacy networks.
HQ CountryGermanyGermanySpain
HQ City
Munich
Bad Rothenfelde
Barcelona
Deal Date16 Jul 202026 Jun 20202 Aug 2018
Valuation$50Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DocMorris acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DocMorris

When was DocMorris founded?DocMorris was founded in 1993.
Where is DocMorris headquartered?DocMorris is headquartered in Switzerland.
How many employees does DocMorris have?As of today, DocMorris has over 1K employees.
Is DocMorris publicly listed?Yes, DocMorris is a public company listed on SIX Swiss Exchange.
What is the stock symbol of DocMorris?DocMorris trades under DOCM ticker.
When did DocMorris go public?DocMorris went public in 2017.
Who are competitors of DocMorris?DocMorris main competitors include Temple & Webster, Nice One, ASOS, JZJ Chain Drugstore, Cawachi, Bed Bath & Beyond, BHG Group, Newegg, Wish, Fanli Digital Technology.
What is the current market cap of DocMorris?DocMorris' current market cap is $446M.
What is the current revenue of DocMorris?DocMorris' last 12 months revenue is $1B.
What is the current revenue growth of DocMorris?DocMorris revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of DocMorris?Current revenue multiple of DocMorris is 0.4x.
Is DocMorris profitable?No, DocMorris is not profitable.
What is the current EBITDA of DocMorris?DocMorris has negative EBITDA and is not profitable.
What is DocMorris' EBITDA margin?DocMorris' last 12 months EBITDA margin is (3%).
What is the current EV/EBITDA multiple of DocMorris?Current EBITDA multiple of DocMorris is (11.5x).
What is the current FCF of DocMorris?DocMorris' last 12 months FCF is ($122M).
What is DocMorris' FCF margin?DocMorris' last 12 months FCF margin is (8%).
What is the current EV/FCF multiple of DocMorris?Current FCF multiple of DocMorris is (4.5x).
How many companies DocMorris has acquired to date?As of June 2026, DocMorris has acquired 3 companies.
What was the largest acquisition by DocMorris?$50M acquisition of TeleClinic on 16th July 2020 was the largest M&A DocMorris has done to date.
What companies DocMorris acquired?DocMorris acquired TeleClinic, Apotal, and PromoFarma.com.
In how many companies DocMorris has invested to date?DocMorris hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to DocMorris

Lists including DocMorris

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial